Amifampridine Phosphate Patent Expiration
Amifampridine Phosphate is Used for treating Lambert-Eaton Myasthenic Syndrome. It was first introduced by Catalyst Pharmaceuticals Inc
Amifampridine Phosphate Patents
Given below is the list of patents protecting Amifampridine Phosphate, along with the drug name that holds that patent and the company name owning that drug.
Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
---|---|---|---|---|
Firdapse | US10626088 | Determining degradation of 3,4-diaminopyridine | Feb 25, 2037 | Catalyst Pharms |
Firdapse | US10793893 | Methods of administering 3,4-diaminopyridine | May 26, 2034 | Catalyst Pharms |
Firdapse | US11060128 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
Firdapse | US11268128 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
Firdapse | US11274331 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
Firdapse | US11274332 | Methods of administering 3,4-diaminopyridine | Jun 29, 2032 | Catalyst Pharms |
Coming Soon
Patent Strength Analyzer
![](/_nuxt/img/PatentAnalyzerAd.722976d.jpg)
YesNo
Thank you for your response 🥳